Details of the Drug Combination

General Information of Drug Combination (ID: DCZV9V9)

• Drug Combination Name: Canagliflozin + AMINOHIPPURIC ACID
• Indication: Type 2 Diabetes; Status: Phase 2 [1]
• Component Drugs:
  Canagliflozin (DMFRM1I): Small molecular drug
  AMINOHIPPURIC ACID (DMUN54G): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Canagliflozin

Disease Entry	ICD 11	Status	REF
Non-insulin dependent diabetes	5A11	Approved	[2]
Type-2 diabetes	5A11	Approved	[3]
Diabetic nephropathy	GB61.Z	Phase 3	[4]
Type-1 diabetes	5A10	Phase 2	[5]

Canagliflozin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sodium/glucose cotransporter 2 (SGLT2)	TTLWPVF	SC5A2_HUMAN	Modulator	[8]

Canagliflozin Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]

Canagliflozin Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[10]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Metabolism	[11]
UDP-glucuronosyltransferase 2B4 (UGT2B4)	DENUPDX	UD2B4_HUMAN	Metabolism	[11]

Canagliflozin Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Sodium/glucose cotransporter 2 (SLC5A2)	OT93UUDI	SC5A2_HUMAN	Decreases Activity	[12]

Indication(s) of AMINOHIPPURIC ACID

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[6]

AMINOHIPPURIC ACID Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Solute carrier family 22 member 8 (SLC22A8)	TTTQR47	S22A8_HUMAN	Inhibitor	[18]

AMINOHIPPURIC ACID Interacts with 9 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[19]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[19]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[20]
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[21]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[22]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[23]
ATP-binding cassette sub-family A member 8 (ABCA8)	DT9NXMV	ABCA8_HUMAN	Substrate	[24]
Sodium-dependent phosphate transport protein 3 (SLC17A2)	DTRF4L3	NPT3_HUMAN	Substrate	[25]
Sodium-dependent phosphate transport protein 4 (SLC17A3)	DTFOJL7	NPT4_HUMAN	Substrate	[26]

AMINOHIPPURIC ACID Interacts with 98 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ABC-type organic anion transporter ABCA8 (ABCA8)	OTCWLX6N	ABCA8_HUMAN	Affects Transport	[24]
Sodium-dependent phosphate transport protein 4 (SLC17A3)	OTMJWIBM	NPT4_HUMAN	Affects Transport	[27]
Organic anion transporter 3 (SLC22A8)	OT8BY933	S22A8_HUMAN	Increases Uptake	[28]
Aryl hydrocarbon receptor repressor (AHRR)	OTSJ12W6	AHRR_HUMAN	Decreases Expression	[29]
Secretory carrier-associated membrane protein 3 (SCAMP3)	OTUNPYCE	SCAM3_HUMAN	Affects Expression	[14]
Glutathione S-transferase A4 (GSTA4)	OTZ1USIA	GSTA4_HUMAN	Affects Expression	[30]
C-X-C motif chemokine 13 (CXCL13)	OT2AT4N8	CXL13_HUMAN	Affects Expression	[14]
Pre-mRNA-processing factor 17 (CDC40)	OTOYUNHN	PRP17_HUMAN	Affects Expression	[30]
Glutathione reductase, mitochondrial (GSR)	OTM2TUYM	GSHR_HUMAN	Affects Expression	[30]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Expression	[31]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Expression	[31]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Increases Expression	[32]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases Expression	[13]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[33]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Affects Expression	[14]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Decreases Methylation	[34]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[35]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Increases Expression	[32]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Expression	[36]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[13]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Phosphorylation	[31]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Increases Activity	[15]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Expression	[13]
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	OTREV92I	CEAM5_HUMAN	Affects Expression	[14]
Tyrosine-protein kinase Lyn (LYN)	OTP686K2	LYN_HUMAN	Affects Expression	[14]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Affects Expression	[14]
Glutathione S-transferase A2 (GSTA2)	OTW7UB1H	GSTA2_HUMAN	Affects Expression	[30]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[37]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[31]
Fibroblast growth factor 6 (FGF6)	OTRJ679P	FGF6_HUMAN	Increases Expression	[13]
Alcohol dehydrogenase class-3 (ADH5)	OTSO67MI	ADHX_HUMAN	Affects Expression	[30]
Cyclic AMP-dependent transcription factor ATF-2 (ATF2)	OTNIZPEA	ATF2_HUMAN	Increases Phosphorylation	[31]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Increases Expression	[13]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Decreases Methylation	[38]
Integrin beta-5 (ITGB5)	OT21MF51	ITB5_HUMAN	Affects Expression	[14]
Syndecan-1 (SDC1)	OTWKRVZC	SDC1_HUMAN	Affects Expression	[14]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B)	OTDS2EAR	TNR1B_HUMAN	Increases Expression	[39]
Proteasome subunit beta type-1 (PSMB1)	OTYRFBAH	PSB1_HUMAN	Affects Expression	[30]
Interleukin-11 (IL11)	OTXHN86R	IL11_HUMAN	Increases Expression	[13]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Affects Expression	[30]
Catechol O-methyltransferase (COMT)	OTPWKTQG	COMT_HUMAN	Affects Expression	[29]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Decreases Expression	[40]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[31]
Proteasome subunit alpha type-1 (PSMA1)	OTNBVM2U	PSA1_HUMAN	Affects Expression	[30]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Affects Expression	[14]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Affects Expression	[30]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[37]
Aryl hydrocarbon receptor nuclear translocator (ARNT)	OTMSIEZY	ARNT_HUMAN	Increases Expression	[33]
Proteasome subunit alpha type-5 (PSMA5)	OT38E6Y1	PSA5_HUMAN	Affects Expression	[30]
Proteasome subunit beta type-5 (PSMB5)	OTOZXAS6	PSB5_HUMAN	Affects Expression	[30]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[37]
Interleukin-12 subunit alpha (IL12A)	OTDQT8GI	IL12A_HUMAN	Decreases Expression	[40]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2)	OTOB6J6R	RIR2_HUMAN	Affects Expression	[30]
Fibroblast growth factor 9 (FGF9)	OT2SKDGM	FGF9_HUMAN	Increases Expression	[13]
Interleukin-13 (IL13)	OTI4YS3Y	IL13_HUMAN	Increases Expression	[32]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Increases Expression	[29]
26S proteasome regulatory subunit 7 (PSMC2)	OTJ4V337	PRS7_HUMAN	Affects Expression	[30]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[13]
N-alpha-acetyltransferase 10 (NAA10)	OTYB9R6I	NAA10_HUMAN	Affects Expression	[30]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[29]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Phosphorylation	[37]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Phosphorylation	[37]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)	OTZPZX11	MP2K4_HUMAN	Increases Phosphorylation	[31]
Glutamate--cysteine ligase catalytic subunit (GCLC)	OTESDI4D	GSH1_HUMAN	Affects Expression	[30]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Affects Expression	[30]
Proteasome subunit beta type-3 (PSMB3)	OTVBON40	PSB3_HUMAN	Affects Expression	[30]
Methionine aminopeptidase 2 (METAP2)	OTNDI7YK	MAP2_HUMAN	Affects Expression	[14]
26S proteasome non-ATPase regulatory subunit 4 (PSMD4)	OTH1VZTM	PSMD4_HUMAN	Affects Expression	[30]
T-cell leukemia/lymphoma protein 1A (TCL1A)	OTPRVZQM	TCL1A_HUMAN	Affects Expression	[14]
26S proteasome regulatory subunit 4 (PSMC1)	OTLHD56E	PRS4_HUMAN	Affects Expression	[30]
Nuclear factor NF-kappa-B p100 subunit (NFKB2)	OTS231V7	NFKB2_HUMAN	Increases Expression	[33]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Affects Expression	[30]
Serine/arginine-rich splicing factor 1 (SRSF1)	OTF61HOV	SRSF1_HUMAN	Affects Expression	[30]
FAS-associated death domain protein (FADD)	OTV7GFHH	FADD_HUMAN	Affects Expression	[14]
Interleukin-27 subunit beta (EBI3)	OT0LF3D7	IL27B_HUMAN	Decreases Expression	[40]
Transmembrane glycoprotein NMB (GPNMB)	OTB7KQKV	GPNMB_HUMAN	Affects Expression	[14]
Splicing factor 3B subunit 3 (SF3B3)	OTAC9LZT	SF3B3_HUMAN	Affects Expression	[30]
Serine/arginine-rich splicing factor 7 (SRSF7)	OTRS4W4S	SRSF7_HUMAN	Affects Expression	[30]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Expression	[41]
Glutathione S-transferase A3 (GSTA3)	OTJ3REE3	GSTA3_HUMAN	Affects Expression	[30]
Heterogeneous nuclear ribonucleoprotein A1-like 2 (HNRNPA1L2)	OTNJ7OTE	RA1L2_HUMAN	Affects Expression	[30]
PHD finger-like domain-containing protein 5A (PHF5A)	OTS94JFM	PHF5A_HUMAN	Affects Expression	[30]
Pre-mRNA-splicing factor 38A (PRPF38A)	OT88097H	PR38A_HUMAN	Affects Expression	[30]
26S proteasome non-ATPase regulatory subunit 1 (PSMD1)	OTW258OV	PSMD1_HUMAN	Affects Expression	[30]
Forkhead box protein P3 (FOXP3)	OTA9Z9OC	FOXP3_HUMAN	Increases Methylation	[32]
Sulfotransferase 1A1 (SULT1A1)	OT0K7JIE	ST1A1_HUMAN	Affects Metabolism	[42]
Solute carrier family 22 member 11 (SLC22A11)	OTAJLNJZ	S22AB_HUMAN	Increases Export	[43]
Epoxide hydrolase 1 (EPHX1)	OTBKWQER	HYEP_HUMAN	Decreases Metabolism	[44]
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Increases Acetylation	[42]
Arylamine N-acetyltransferase 1 (NAT1)	OTCCNQ3H	ARY1_HUMAN	Increases Acetylation	[42]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Increases Response To Substance	[45]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Increases Uptake	[46]
Glutathione S-transferase Mu 3 (GSTM3)	OTLA2WJT	GSTM3_HUMAN	Increases Response To Substance	[47]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Increases Metabolism	[44]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Affects Response To Substance	[48]
Glutathione S-transferase theta-1 (GSTT1)	OTRFMWBK	GSTT1_HUMAN	Decreases Activity	[42]
Glutathione S-transferase Mu 1 (GSTM1)	OTSBF2MO	GSTM1_HUMAN	Increases Response To Substance	[49]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Affects Response To Substance	[50]

References

• [1] ClinicalTrials.gov (NCT05507892) Renal Mechanism of SGLT2 Inhibition
• [2] Canagliflozin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4582).
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4810).
• [7] Evaluation of inhibitors of intestinal UDP-glucuronosyltransferases 1A8 and 1A10 using raloxifene as a substrate in Caco-2 cells: Studies with four flavonoids of Scutellaria baicalensis. Toxicol In Vitro. 2021 Apr;72:105087. doi: 10.1016/j.tiv.2021.105087. Epub 2021 Jan 10.
• [8] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [9] In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
• [10] Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62.
• [11] Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
• [12] Discovery of novel N--D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem. 2011 Jan 13;54(1):166-78. doi: 10.1021/jm101072y. Epub 2010 Dec 3.
• [13] Induction of fibroblast growth factor-9 and interleukin-1alpha gene expression by motorcycle exhaust particulate extracts and benzo(a)pyrene in human lung adenocarcinoma cells. Toxicol Sci. 2005 Oct;87(2):483-96. doi: 10.1093/toxsci/kfi251. Epub 2005 Jul 7.
• [14] Cancer-related proteins in serum are altered in workers occupationally exposed to polycyclic aromatic hydrocarbons: a cross-sectional study. Carcinogenesis. 2019 Jul 6;40(6):771-781. doi: 10.1093/carcin/bgz022.
• [15] Protein tyrosine kinase activation by polycyclic aromatic hydrocarbons in human HPB-ALL T cells. J Toxicol Environ Health A. 1999 Feb 26;56(4):249-61. doi: 10.1080/009841099158097.
• [16] Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. Pharmacogenet Genomics. 2011 Feb;21(2):55-65. doi: 10.1097/FPC.0b013e328341db05.
• [17] Interactions between exposure to environmental polycyclic aromatic hydrocarbons and DNA repair gene polymorphisms on bulky DNA adducts in human sperm. PLoS One. 2010 Oct 5;5(10):e13145. doi: 10.1371/journal.pone.0013145.
• [18] Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
• [19] ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
• [20] Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
• [21] Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg Med (Tokyo). 2011 Jul;13(4):180-5.
• [22] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [23] Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E390-8.
• [24] Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
• [25] Wide expression of type I Na+-phosphate cotransporter 3 (NPT3/SLC17A2), a membrane potential-driven organic anion transporter. Am J Physiol Cell Physiol. 2015 Jul 15;309(2):C71-80.
• [26] Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010 Nov 5;285(45):35123-32.
• [27] Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. J Pharmacol Sci. 2011;115(2):249-53. doi: 10.1254/jphs.10228sc. Epub 2011 Jan 26.
• [28] Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
• [29] Effects of human blood levels of two PAH mixtures on the AHR signalling activation pathway and CYP1A1 and COMT target genes in granulosa non-tumor and granulosa tumor cell lines. Toxicology. 2017 Aug 15;389:1-12. doi: 10.1016/j.tox.2017.07.003. Epub 2017 Jul 11.
• [30] Identification of molecular signatures predicting the carcinogenicity of polycyclic aromatic hydrocarbons (PAHs). Toxicol Lett. 2012 Jul 7;212(1):18-28. doi: 10.1016/j.toxlet.2012.04.013. Epub 2012 May 1.
• [31] Nanomolar levels of PAHs in extracts from urban air induce MAPK signaling in HepG2 cells. Toxicol Lett. 2014 Aug 17;229(1):25-32. doi: 10.1016/j.toxlet.2014.06.013. Epub 2014 Jun 6.
• [32] Childhood exposure to ambient polycyclic aromatic hydrocarbons is linked to epigenetic modifications and impaired systemic immunity in T cells. Clin Exp Allergy. 2015 Jan;45(1):238-48. doi: 10.1111/cea.12377.
• [33] Compounds of PAH mixtures dependent interaction between multiple signaling pathways in granulosa tumour cells. Toxicol Lett. 2019 Aug;310:14-22. doi: 10.1016/j.toxlet.2019.04.008. Epub 2019 Apr 10.
• [34] Shorter telomere length in peripheral blood lymphocytes of workers exposed to polycyclic aromatic hydrocarbons. Carcinogenesis. 2010 Feb;31(2):216-21. doi: 10.1093/carcin/bgp278. Epub 2009 Nov 5.
• [35] Effect of artificial mixtures of environmental polycyclic aromatic hydrocarbons present in coal tar, urban dust, and diesel exhaust particulates on MCF-7 cells in culture. Environ Mol Mutagen. 2004;44(2):99-107. doi: 10.1002/em.20039.
• [36] Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005 May;61(3):197-201. doi: 10.1007/s00228-005-0908-7. Epub 2005 Apr 12.
• [37] Differential proinflammatory responses induced by diesel exhaust particles with contrasting PAH and metal content. Environ Toxicol. 2015 Feb;30(2):188-96. doi: 10.1002/tox.21884. Epub 2013 Jul 31.
• [38] Global and MGMT promoter hypomethylation independently associated with genomic instability of lymphocytes in subjects exposed to high-dose polycyclic aromatic hydrocarbon. Arch Toxicol. 2013 Nov;87(11):2013-2022. doi: 10.1007/s00204-013-1046-0. Epub 2013 Mar 30.
• [39] Association of biomarkers of systemic inflammation with organic components and source tracers in quasi-ultrafine particles. Environ Health Perspect. 2010 Jun;118(6):756-62. doi: 10.1289/ehp.0901407. Epub 2010 Feb 2.
• [40] The impact on T-regulatory cell related immune responses in rural women exposed to polycyclic aromatic hydrocarbons (PAHs) in household air pollution in Gansu, China: A pilot investigation. Environ Res. 2019 Jun;173:306-317. doi: 10.1016/j.envres.2019.03.053. Epub 2019 Mar 26.
• [41] Occupational exposure to polycyclic aromatic hydrocarbons suppresses constitutive expression of CYP1B1 on the transcript level in human leukocytes. Int J Hyg Environ Health. 2004 Sep;207(4):325-35. doi: 10.1078/1438-4639-00298.
• [42] GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004 Jul 1;110(4):598-604. doi: 10.1002/ijc.20157.
• [43] Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology. 2009 Oct 1;264(1-2):74-9. doi: 10.1016/j.tox.2009.07.014. Epub 2009 Jul 28.
• [44] Occupational exposure to polycyclic aromatic hydrocarbons in German industries: association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphisms. Toxicol Lett. 2005 Jul 4;157(3):241-55. doi: 10.1016/j.toxlet.2005.02.012. Epub 2005 Apr 8.
• [45] [Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer]. J Prev Med Public Health. 2005 Aug;38(3):345-50.
• [46] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [47] A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res. 2001 Mar 15;61(6):2381-5.
• [48] Modulation of DNA repair capacity by ataxia telangiectasia mutated gene polymorphisms among polycyclic aromatic hydrocarbons-exposed workers. Toxicol Sci. 2011 Nov;124(1):99-108. doi: 10.1093/toxsci/kfr216. Epub 2011 Aug 26.
• [49] Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics. 2001 Dec;11(9):757-64. doi: 10.1097/00008571-200112000-00003.
• [50] [A study on the inherited susceptibility of chromosomal damage in peripheral blood lymphocytes among coke oven workers]. Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Mar;38(2):94-8.